---
figid: PMC6046285__atm-06-12-253-f1
figlink: /pmc/articles/PMC6046285/figure/f1/
number: F1
caption: Major signaling pathways activated through IGF-1R and EGF-R in adrenocortical
  carcinoma. Activation of PI3K/AKT/mTOR and MAPK (Ras/Raf/MEK/ERK) intracellular
  pathway by either receptor results in cell survival, proliferation and tumor growth.
  Corresponding downstream molecules inhibitors (rosiglitazone, metformin, temsirolimus)
  and antibodies that target directly EGFR (erlotinib), IGF-1R (figitumumab, cetuximab)
  and IGF-1 (IMC-A12) are shown in this figure. IGF-2R lacks tyrosine kinase activity.
  EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; IGF-1, insulin-like
  growth factor; IGF-1R, insulin-like growth factor-1 receptor; IGFBP, insulin growth
  factor binding proteins; IRS, insulin receptor substrate; SHC, SHC adaptor protein;
  PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target
  of rapamycin; RAS, rat sarcoma viral oncogene homolog; RAF, rapidly accelerated
  fibrosarcoma; MEK, mitogen-activated protein kinase/extracellular signal-regulated
  kinase; ERK, extracellular signal-regulated kinase.
pmcid: PMC6046285
papertitle: The role of epithelial growth factors and insulin growth factors in the
  adrenal neoplasms.
reftext: Anna Angelousi, et al. Ann Transl Med. 2018 Jun;6(12):253.
pmc_ranked_result_index: '156449'
pathway_score: 0.9738124
filename: atm-06-12-253-f1.jpg
figtitle: Major signaling pathways activated through IGF-1R and EGF-R in adrenocortical
  carcinoma
year: '2018'
organisms:
- Homo sapiens
ndex: 8a73d1f4-debe-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6046285__atm-06-12-253-f1.html
  '@type': Dataset
  description: Major signaling pathways activated through IGF-1R and EGF-R in adrenocortical
    carcinoma. Activation of PI3K/AKT/mTOR and MAPK (Ras/Raf/MEK/ERK) intracellular
    pathway by either receptor results in cell survival, proliferation and tumor growth.
    Corresponding downstream molecules inhibitors (rosiglitazone, metformin, temsirolimus)
    and antibodies that target directly EGFR (erlotinib), IGF-1R (figitumumab, cetuximab)
    and IGF-1 (IMC-A12) are shown in this figure. IGF-2R lacks tyrosine kinase activity.
    EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; IGF-1, insulin-like
    growth factor; IGF-1R, insulin-like growth factor-1 receptor; IGFBP, insulin growth
    factor binding proteins; IRS, insulin receptor substrate; SHC, SHC adaptor protein;
    PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target
    of rapamycin; RAS, rat sarcoma viral oncogene homolog; RAF, rapidly accelerated
    fibrosarcoma; MEK, mitogen-activated protein kinase/extracellular signal-regulated
    kinase; ERK, extracellular signal-regulated kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT2
  - IGFBP4
  - EGF
  - IGFBP3
  - SHC4
  - IGFBP6
  - EGFR
  - IGFBP2
  - RAF1
  - BRAF
  - HRAS
  - KRAS
  - NRAS
  - SHC2
  - MAPK3
  - SHC3
  - SHC1
  - IGF2R
  - MAP2K1
  - IGFBP1
  - ARAF
  - AKT3
  - AKT1
  - IRS1
  - IGF1
  - IGFBP5
  - MAPK1
  - IGFBP7
  - MAP2K2
  - IGF1R
  - IGF2
  - MTOR
  - IRS4
  - IRS2
  - Erlotinib
  - IMC
  - tyrosine
  - Rosiglitazone
  - Temsirolimus
  - Metformin
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP4
  entrez: '3487'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP3
  entrez: '3486'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC4
  entrez: '399694'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP6
  entrez: '3489'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP2
  entrez: '3485'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC2
  entrez: '25759'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC3
  entrez: '53358'
- word: SHC
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC1
  entrez: '6464'
- word: IGF-2R
  symbol: IGF2R
  source: hgnc_symbol
  hgnc_symbol: IGF2R
  entrez: '3482'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP1
  entrez: '3484'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: IGF-1
  symbol: IGF1
  source: hgnc_symbol
  hgnc_symbol: IGF1
  entrez: '3479'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP5
  entrez: '3488'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP7
  entrez: '3490'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: IGF-1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: IGF-2
  symbol: IGF-II
  source: hgnc_alias_symbol
  hgnc_symbol: IGF2
  entrez: '3481'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS4
  entrez: '8471'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS2
  entrez: '8660'
chemicals:
- word: Erlotinib
  source: MESH
  identifier: C400278
- word: IMC
  source: MESH
  identifier: C020760
- word: tyrosine
  source: ''
  identifier: ''
- word: Rosiglitazone
  source: MESH
  identifier: C089730
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Metformin
  source: MESH
  identifier: D008687
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC6046285__F1
redirect_from: /figures/PMC6046285__F1
figtype: Figure
---
